Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 4,589 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Crossover Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Smoking and Ventricular Repolarization

NCT03916341
View directory record Official record
Conditions
Sudden Cardiac Death, Prolonged QTc Interval
Interventions
EC with nicotine, EC without nicotine, control, TC with nicotine (own brand), research TC with very low level nicotine
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 24, 2026, 8:52 AM EDT
Recruiting Not applicable Interventional

SCS for Patient With Painful Diabetic Neuropathy and Peripheral Arterial Disease

NCT06480786
View directory record Official record
Conditions
Peripheral Arterial Disease, Painful Diabetic Neuropathy, Diabetes Mellitus, Type 2, Chronic Pain, Spinal Cord Stimulation, Chronic Pain Syndrome, Limb Pain
Interventions
Spinal cord stimulation, Sham stimulation
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 24, 2026, 8:52 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pilot Study of Fisetin to Improve Fatigue Among Older Adult Cancer Survivors

NCT06819254
View directory record Official record
Conditions
Fatigue
Interventions
Fisetin followed by Placebo, Placebo followed by Fisetin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

NCT01530542
View directory record Official record
Conditions
Analgesia, Acute Pain, Chronic Pain, Narcotic Abuse, Opioid-related Disorders
Interventions
oxycodone hydrochloride, marketed oxycodone hydrochloride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

NCT02158520
View directory record Official record
Conditions
Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Unresectable Melanoma
Interventions
Bevacizumab, Ipilimumab, Laboratory Biomarker Analysis, Nab-paclitaxel, Pharmacological Study
Biological · Other · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
13
States / cities
San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 4 Interventional Results available

Effects of Oxytocin on Behavior and Physiology in a Psychotherapy Setting

NCT01081249
View directory record Official record
Conditions
Behavior, Anxiety
Interventions
Placebo then intranasal oxytocin, Intranasal oxytocin then placebo
Drug
Lead sponsor
MacDonald, Kai, M.D.
Individual
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 24, 2026, 8:52 AM EDT
Recruiting Phase 2 Interventional

Study to Improve Deployment Related Asthma by Using L-Citrulline Supplementation

NCT05259904
View directory record Official record
Conditions
Post Deployment Related Asthma, Asthma
Interventions
L-citrulline, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

NCT04054206
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MN-166
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

NCT00532610
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness Research to Enhance Outcomes in African-Americans With Obstructive Sleep Apnea

NCT01997723
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Portable monitoring, Polysomnography, Home portable monitoring, Laboratory portable monitoring
Device · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

NCT00316459
View directory record Official record
Conditions
Healthy, Long QT Syndrome
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2007 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 4 Interventional Results available

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

NCT02038790
View directory record Official record
Conditions
Opioid Dependence
Interventions
Suboxone Sublingual Film, Zubsolv sublingual tablets
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 24, 2026, 8:52 AM EDT
Terminated Phase 2 Interventional Results available

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

NCT02168062
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Behavioral Dietary Intervention, Counseling, Educational Intervention, Exercise Intervention, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment, Triptorelin Pamoate
Behavioral · Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Not applicable Interventional

Incremental Velocity Error as a New Treatment in Vestibular Rehabilitation

NCT03846830
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Vestibular Neuropathy
Interventions
Incremental Velocity Error (IVE), Traditional Vestibular Rehabilitation (VPT)
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 24, 2026, 8:52 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

tDCS for Cancer-Related Fatigue and Weakness

NCT07159100
View directory record Official record
Conditions
Cancer-related Fatigue, Neuromodulation
Interventions
Active tDCS + elbow flexion exercise, Sham tDCS + elbow flexion exercise
Device · Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
40 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma

NCT00033293
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin
Other · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 8 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
97
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women

NCT00796133
View directory record Official record
Conditions
Ovulation
Interventions
NES/E2 gel
Drug
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

NCT04470778
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986256, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 24, 2026, 8:52 AM EDT
Not listed Not applicable Interventional

Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration

NCT02379689
View directory record Official record
Conditions
Degenerative Disc Disease, Pain
Interventions
Injectable placental tissue extract called BioDGenesis (Active Product), Placebo
Drug
Lead sponsor
Semmes-Murphey Foundation
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Puyallup, Washington, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

NCT02753764
View directory record Official record
Conditions
Corticosteroid Resistant (CR) Asthmatics
Interventions
AZD7624, prednisone, Placebo
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 24, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Oral Bioavailability of Remimazolam

NCT04113564
View directory record Official record
Conditions
Bioavailability
Interventions
Remimazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 24, 2026, 8:52 AM EDT